MedPath

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Phase 3
Active, not recruiting
Conditions
Head and Neck Cancer
Interventions
Radiation: IMRT
Drug: Placebo
Registration Number
NCT05386550
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Brief Summary

The purpose of this study is to demonstrate the superior efficacy of Xevinapant (Debio 1143) versus placebo when added to radiotherapy in the treatment of high-risk participants with resected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) who are ineligible to receive cisplatin-based chemoradiation concurrently. Study details include: Study duration: Participants will be followed until the last on-study participant reaches his/her 60-month post-randomization visit, a decision to end the study has been triggered, or until premature discontinuation from study, whichever occurs first. Treatment duration: 18 weeks, consisting of six 3-week cycles. Health measurement/observation: Improved Disease-Free Survival. Visit frequency: Weekly visit during combination therapy period, once every 3 weeks during monotherapy period, and every 3, 4, or 6 months during the Disease-Free Survival Follow-up period in Year 1, 2 and 3, or 4 and 5 (with telephone contact in between), respectively, and every 3 months (telephone visits allowed) during the Overall Survival Follow-up period.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
166
Inclusion Criteria
  • Participants with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2 and able to tolerate standard of care IMRT treatment according to Investigator assessment
  • Participants with histologically confirmed squamous cell carcinoma with one of the following primary sites: oral cavity, oropharynx, hypopharynx or larynx. Participants have received surgery with curative intent on these sites in the past 4 to 10 weeks before start of treatment (Cycle 1 Day 1)
  • Oropharynx (OPC) participants must have known human papillomavirus (HPV) status as determined by p16 expression using immunohistochemistry (ICH)
  • Participants with no residual disease by computed tomography (CT) or magnetic resonance imaging (MRI) and have a high risk of relapse with 1 or 2 of the following criteria, confirmed by local histopathology: • nodal extra-capsular extension (ECE) and positive resection margins (R1 or close margin less than or equal to (<=) 1 millimeter (mm)
  • Are unfit to receive high-dose cisplatin by meeting one or more of the following criteria: estimated glomerular filtration rate (eGFR) < 60 milliliter per minute per 1.73 meter square (mL/min /1.73 m^2); History of hearing impairment, defined as Grade >= 2 audiometric hearing loss or tinnitus Grade >= 2. An audiogram is not required if one of the other criteria meets unfitness to receive high-dose cisplatin; Peripheral neuropathy > = Grade 2 and if >= 70 years, unfit according to G8 questionnaire (Score <= 14) or ineligible for cisplatin treatment due to age limit according to national guidelines
  • Participants with adequate renal, hematologic and hepatic function as defined in the protocol
  • Other protocol-defined inclusion criteria could apply
Exclusion Criteria
  • Any condition, including any uncontrolled disease state other than SCCHN that in the Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
  • Participants with incomplete surgery
  • Participants with recurrent or metastatic disease
  • Primary tumor of nasopharyngeal, paranasal sinuses, nasal cavity, salivary, thyroid or parathyroid gland, skin or unknown primary site
  • Prior definitive, neoadjuvant, concurrent or adjuvant (C)RT to the head and neck region which may jeopardize the primary tumor irradiation plan, or any other prior SCCHN systemic treatment, including investigational agents
  • Participation in any interventional clinical study within 28 days prior to screening or during participation in this study
  • Known contraindication to undergoing positron emission tomography with 18F-FDG-PET-CT scans, or both contrast-enhanced MRI and contrast-enhanced CT scans
  • Known allergy to Xevinapant (Debio 1143) or any excipient known to be present in Xevinapant (Debio 1143) or in the placebo formulation
  • Other protocol-defined exclusion criteria could apply

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm A: Xevinapant (Debio 1143) + IMRTIMRT-
Arm B: Placebo + IMRTIMRT-
Arm B: Placebo + IMRTPlacebo-
Arm A: Xevinapant (Debio 1143) + IMRTXevinapant (Debio 1143)-
Primary Outcome Measures
NameTimeMethod
Disease-Free Survival (DFS)Time from randomization to the first occurrence of death from any cause or objective disease recurrence, assessed up to 5 years
Secondary Outcome Measures
NameTimeMethod
Overall Survival (OS)Time from randomization to death from any cause, assessed up to 5 years
Change from Baseline in EuroQOL 5 Dimension 5 Level Health-Related Quality of Life Measure Visual Analog Scale Score (EQ-5D-5L VAS)Baseline, Day 64 [at Week 10 (each cycle is 3 weeks)] and End of treatment Day 134 (at Week 20)
Change from Baseline in European Organization for research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) ScoreBaseline, Day 64 [at Week 10 (each cycle is 3 weeks)] and End of treatment Day 134 (at Week 20)
Time to Subsequent Cancer TreatmentsTime from randomization to the start of first subsequent cancer treatment, assessed up to 5 years
Number of Participants with Adverse Events (AEs) and Treatment-related AEsTime from randomization until end of study (up to 5 years)
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN35) ScoreBaseline, Day 64 [at Week 10 (each cycle is 3 weeks)] and End of treatment Day 134 (at Week 20)

Trial Locations

Locations (206)

University of Pittsburgh Medical Center Health System - UPMC Department of Dermatology

🇺🇸

Pittsburgh, Pennsylvania, United States

Xiangya Hospital, Central South University

🇨🇳

Changsha, China

Union Hospital, Tongji Medical College of Huazhong University of Science & Technology

🇨🇳

Wuhan, China

Henan Cancer Hospital

🇨🇳

Zhengzhou, China

Barbara Ann Karmanos Cancer Institute

🇺🇸

Detroit, Michigan, United States

Krankenhaus der barmherzigen Schwestern Linz - Abteilung für HNO

🇦🇹

Linz, Austria

LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie

🇦🇹

Salzburg, Austria

High Technology Medical Center, University Clinic

🇬🇪

Tbilisi, Georgia

Tata Medical Centre

🇮🇳

Kolkata, India

All India Institute of Medical Sciences

🇮🇳

New Delhi, India

Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez

🇲🇽

Monterrey, Mexico

Chang Gung Memorial Hospital,Linkou

🇨🇳

Taoyuan, Taiwan

JSC EVEX Hospitals

🇬🇪

Kutaisi, Georgia

General Hospital of Athens of Chest Diseases "SOTIRIA" - Sotiria Thoracic Diseases Hospital of Athens

🇬🇷

Athens, Greece

Universitaetsspital Basel - Klinik fuer Strahlentherapie und Radioonkologie

🇨🇭

Basel, Switzerland

Universitaetsspital Zuerich - Parent

🇨🇭

Zuerich, Switzerland

Kaohsiung Medical University Chung-Ho Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

New Hospitals

🇬🇪

Tbilisi, Georgia

University General Hospital "Attikon"

🇬🇷

Athens, Greece

Interbalkan Hospital of Thessaloniki

🇬🇷

Thessaloniki, Greece

National Cancer Institute Nagpur

🇮🇳

Nagpur, India

Regional Cancer Centre

🇮🇳

Thiruvananthapuram, India

Hospital de Braga - Serviço de Oncologia Medica

🇵🇹

Braga, Portugal

Centrul medical Focus

🇷🇴

Bucuresti, Romania

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, Państwowy Instytut Badawczy - Zakład Medycyny Nuklearnej i Endokrynologii Onkolo

🇵🇱

Gliwice, Poland

Kaohsiung Chang Gung Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

National Cheng Kung University Hospital

🇨🇳

Tainan, Taiwan

Musgrove Park Hospital - PARENT

🇬🇧

Somerset, United Kingdom

S.C Radiotherapy Center Cluj S.R.L - Parent

🇷🇴

ComunaFloresti, Romania

S.C Oncocenter Oncologie Clinica S.R.L - parent

🇷🇴

Timisoara, Romania

China Medical University Hospital

🇨🇳

Taichung, Taiwan

Complejo Hospitalario Universitario Insular Materno-Infantil - Servicio de Oncologia

🇪🇸

Las Palmas de Gran Canaria, Spain

The Christie Hospital - Dept of Oncology

🇬🇧

Manchester, United Kingdom

Fondazione IRCCS Istituto Nazionale dei Tumori - S.S. Tumori della Testa e del Collo

🇮🇹

Milano, Italy

Mount Vernon Cancer Centre

🇬🇧

Northwood, United Kingdom

The Royal Marsden NHS Foundation Trust

🇬🇧

Sutton, United Kingdom

Torbay Hospital - PARENT

🇬🇧

Torquay, United Kingdom

Clatterbridge Cancer Centre

🇬🇧

Wirral, United Kingdom

Oncosite - Centro de Pesquisa Clinica e Oncologia

🇧🇷

Ijui, Brazil

Irmandade da Santa Casa de Misericórdia de Porto Alegre

🇧🇷

Porto Alegre, Brazil

INCA - Instituto Nacional de Câncer

🇧🇷

Rio de Janeiro, Brazil

Centre Francois Baclesse - Service d'Oncologie Medicale

🇫🇷

Caen Cedex 05, France

Centre Georges François Leclerc - Oncologie Médicale

🇫🇷

Dijon, France

Hopital Prive Drome Ardeche - Service D Oncologie

🇫🇷

Guilherand Granges, France

Centre Henri Becquerel - Service de radiothérapie

🇫🇷

Rouen, France

Hadassah University Hospital - Ein Kerem

🇮🇱

Yerushalayim, Israel

Fakultni nemocnice Bulovka - Dept of Radiodiagnosticka klinika

🇨🇿

Praha, Czechia

Hospital Santa Izabel - Santa Casa de Misericórdia da Bahia

🇧🇷

Salvador, Brazil

University of Alabama at Birmingham - Dept of Radiation Oncology

🇺🇸

Birmingham, Alabama, United States

The University of Arizona Cancer Center

🇺🇸

Tucson, Arizona, United States

Dana-Farber Cancer Institute

🇺🇸

Boston, Massachusetts, United States

UC Health

🇺🇸

Aurora, Colorado, United States

Montefiore Medical Center Radiology

🇺🇸

Bronx, New York, United States

Perlmutter Cancer Center at NYU Langone Hospital ae Long Island

🇺🇸

New York, New York, United States

University of Cincinnati Cancer Institute

🇺🇸

Cincinnati, Ohio, United States

Prisma Health Cancer Institute, ITOR, CRU

🇺🇸

Greenville, South Carolina, United States

CEMAIC- Centro Medico Privado

🇦🇷

Las Margaritas, Argentina

Centro Oncologico Riojano Integral (CORI)

🇦🇷

La Rioja, Argentina

Instituto de Oncologia Angel Roffo

🇦🇷

Ciudad Autonoma Buenos Aires, Argentina

Fundacion Scherbovsky

🇦🇷

Mendoza, Argentina

Universitatsklinikum Graz

🇦🇹

Graz, Austria

Clinica Viedma S.A.

🇦🇷

Viedma, Argentina

Cliniques Universitaires Saint-Luc - STL

🇧🇪

Bruxelles, Belgium

Institut Jules Bordet - Medical Oncology

🇧🇪

Anderlecht, Belgium

Antwerp University Hospital (UZA Parent)

🇧🇪

Edegem, Belgium

Vitaz

🇧🇪

Sint-Niklaas, Belgium

Hospital de Câncer de Barretos - Fundação Pio XII - Hospital de Amor

🇧🇷

Barretos, Brazil

Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer

🇧🇷

Curitiba, Brazil

CRIO - Centro Regional Integrado de Oncologia

🇧🇷

Fortaleza, Brazil

CEPON - Centro de Pesquisas Oncológicas de Santa Catarina - Pesquisa Clínica

🇧🇷

Florianópolis, Brazil

Grupo Oncoclínicas

🇧🇷

Rio de Janeiro, Brazil

Instituto de Cancer de Londrina

🇧🇷

Londrina, Brazil

Liga Norte-Rio-Grandense Contra o Câncer

🇧🇷

Natal, Brazil

HGB - Hospital Giovanni Battista - Mãe de Deus Center

🇧🇷

Porto Alegre, Brazil

Hospital de Clínicas de Porto Alegre

🇧🇷

Porto Alegre, Brazil

CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC

🇧🇷

Santo André, Brazil

BP A Beneficencia Portuguesa da Sao Paulo

🇧🇷

São Paulo, Brazil

ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira

🇧🇷

São Paulo, Brazil

Centre Hospitalier de l'Universite de Montreal.

🇨🇦

Montreal, Canada

Hospital of Bengbu Medical College

🇨🇳

Bengbu, China

Beijing Cancer Hospital

🇨🇳

Beijing, China

Hunan Cancer Hospital

🇨🇳

Changsha, China

Sichuan Cancer Hospital

🇨🇳

Chengdu, China

The First Hospital of Jilin University

🇨🇳

Changchun, China

West China Hospital, Sichuan University

🇨🇳

Chengdu, China

Chongqing University Cancer Hospital

🇨🇳

Chongqing, China

Fujian Cancer Hospital

🇨🇳

Fuzhou, China

Sun Yat-sen University Cancer Center

🇨🇳

Guangzhou, China

Sir Run Shaw Hospital, Zhejiang University, School of Medicine

🇨🇳

Hangzhou, China

Zhejiang Cancer Hospital

🇨🇳

Hangzhou, China

Shandong Cancer Hospital

🇨🇳

Jinan, China

Anhui Provincial Cancer Hospital

🇨🇳

Hefei, China

Nanjing Drum Tower Hospital

🇨🇳

Nanjing, China

Jiangxi Cancer Hospital

🇨🇳

Nanchang, China

Guangxi Medical University Affiliated Tumor Hospital

🇨🇳

Nanning, China

Fudan University Shanghai Cancer Center

🇨🇳

Shangai, China

Shanghai General Hospital

🇨🇳

Shanghai, China

The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital)

🇨🇳

Xi'an, China

Shengjing Hospital of China Medical University

🇨🇳

Shenyang, China

Tianjin Medical University Cancer Institute & Hospital

🇨🇳

Tianjin, China

Northern Jiangsu People's Hospital

🇨🇳

Yangzhou, China

Fakultni nemocnice Olomouc - Dept of Onkologicka klinika

🇨🇿

Olomouc, Czechia

Fakultni nemocnice Kralovske Vinohrady - Dept of Radioterapeuticka a onkologicka klinika

🇨🇿

Praha 10, Czechia

ICO - Site Paul Papin - service d'oncologie medicale

🇫🇷

Angers Cedex 2, France

CHU Bordeaux - Service d'Oncologie Médicale

🇫🇷

Bordeaux, France

CHU Brest - Hôpital Morvan - Service d'Oncologie Médicale

🇫🇷

Brest Cedex, France

Centre Hospitalier de Bretagne Sud

🇫🇷

Lorient cedex, France

Clinique Victor Hugo - Centre Jean Bernard - Service d'Oncologie Médicale

🇫🇷

Le Mans, France

Centre Hospitalier de la Croix Rousse - Service ORL et chirurgie cervico-faciale

🇫🇷

Lyon, France

Centre Oscar Lambret - service de cancerologie gynecologique

🇫🇷

Lille cedex, France

Hôpital de la Timone - Oncologie Médicale Hématologie & Soins Palliatifs

🇫🇷

Marseille Cedex 5, France

Centre Antoine Lacassagne - Service d'Hématologie Oncologie

🇫🇷

Nice cedex 02, France

Institut Régional du Cancer de Montpellier - Service de Professeur Senesse

🇫🇷

Montpellier, France

Centre Azureen Cancerologie - Service De Radiotherapie

🇫🇷

Mougins, France

Institut Curie - site de Paris - Service d'Oncologie Médicale

🇫🇷

Paris Cedex 05, France

CHU Poitiers - Hôpital la Milétrie - service d'oncologie médicale

🇫🇷

Poitiers, France

Institut de Cancérologie de Strasbourg Europe - ICANS - Service d'oncologie médicale

🇫🇷

Strasbourg Cedex, France

Centre Hospitalier Privé Saint-Gregoire (Rennes) - Cancerologie

🇫🇷

Saint Grégoire, France

Hopital Tenon - service radiologie et imagerie medicale

🇫🇷

Paris cedex, France

ICO - Site René Gauducheau - Service d'Oncologie medicale

🇫🇷

Saint Herblain, France

Institut Claudius Regaud - service de Radiothérapie

🇫🇷

Toulouse cedex 09, France

CHI Toulon La Seyne - Hôpital Sainte Musse - Service d'Onco-Hematologie

🇫🇷

Toulon cedex, France

CHU Tours - Hôpital Bretonneau - Service d'Oncologie Médicale

🇫🇷

Tours, France

Cancer Research Center Ltd.

🇬🇪

Tbilisi, Georgia

Institut Gustave Roussy - Oncologie Médicale

🇫🇷

Villejuif cedex, France

High Technology Hospital Medcenter LLC

🇬🇪

Batumi, Georgia

LLC Todua Clinic

🇬🇪

Tbilisi, Georgia

Vivantes Klinikum Neukoelln - Parent

🇩🇪

Berlin, Germany

Universitaetsmedizin Goettingen - Georg-August-Universität

🇩🇪

Goettingen, Germany

Universitaetsklinikum Giessen und Marburg GmbH Standort Giessen - Hals-, Nasen- und Ohrenklinik

🇩🇪

Giessen, Germany

Universitaetsklinikum Jena - HNO_Klinik

🇩🇪

Jena, Germany

Universitaetsklinikum Schleswig-Holstein - Campus Kiel - Klinik für diagnostische Radiologie

🇩🇪

Kiel, Germany

Universitaetsklinikum Leipzig - Klinik fuer Strahlentherapie und Radioonkologie

🇩🇪

Leipzig, Germany

Universitaetsmedizin Rostock - Klinik und Poliklinik für Strahlentherapie

🇩🇪

Rostock, Germany

Soroka University Medical Center

🇮🇱

Beer sheva, Israel

Rambam Health Care Campus

🇮🇱

Haifa, Israel

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili) - Oncologia Medica

🇮🇹

Brescia, Italy

Ospedale Oncologico Armando Businco - Divisione di Oncologia Medica II

🇮🇹

Cagliari, Italy

Fondazione del Piemonte per l'Oncologia IRCC Candiolo - Div. di Oncologia Medica ed Ematologia

🇮🇹

Candiolo, Italy

Azienda Ospedaliera Universitaria Careggi - S.O.D. di Oncologia Medica

🇮🇹

Firenze, Italy

IRCCS Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori "Dino Amadori" - IRST - U. Operativa di Immunoterapia e Terapia Cellulare

🇮🇹

Meldola, Italy

Ospedale San Raffaele - U.O. di Oncologia Medica

🇮🇹

Milano, Italy

A.O.U. Policlinico di Modena - U.O. Oncologia

🇮🇹

Modena, Italy

Azienda Ospedaliera Universitaria- Università degli Studi della Campania "Luigi Vanvitelli" - Dipartimento Oncologia

🇮🇹

Napoli, Italy

IEO Istituto Europeo di Oncologia - Divisione Oncologia Medica

🇮🇹

Milano, Italy

Istituto Nazionale Tumori Fondazione G. Pascale - Oncologia Medica A

🇮🇹

Napoli, Italy

IOV - Istituto Oncologico Veneto IRCCS - Oncologia Medica 2

🇮🇹

Padova, Italy

Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza - U.O.C. di Oncologia B

🇮🇹

Roma, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Radioterapia 1

🇮🇹

Roma, Italy

National Cancer Center Hospital - Dept of Gastroenterology

🇯🇵

Chuo-ku, Japan

Hyogo Cancer Center - Dept of Head and Neck Surgery

🇯🇵

Akashi-shi, Japan

Istituto Clinico Humanitas - U.O. di Oncologia Medica ed Ematologia

🇮🇹

Rozzano, Italy

NHO Kyushu Cancer Center - Dept of Head and Neck Surgery

🇯🇵

Fukuoka-shi, Japan

Kagawa University Hospital - Dept of Oncology

🇯🇵

Kita-gun, Japan

Saitama Medical University International Medical Center - Dept of Otorhinolaryngology/ Head and Neck Surgery

🇯🇵

Hidaka-shi, Japan

Hiroshima University Hospital - Dept of Otorhinolaryngology/ Head and Neck Surgery

🇯🇵

Hiroshima-shi, Japan

National Cancer Center Hospital East - Dept of Head and Neck Medical Oncology

🇯🇵

Kashiwa-shi, Japan

Saitama Cancer Center - Dept of Head and Neck Surgery

🇯🇵

Kitaadachi-gun, Japan

Kobe University Hospital - Dept of Oncology/Hematology

🇯🇵

Kobe-shi, Japan

Nagoya University Hospital - Dept of Otorhinolaryngology

🇯🇵

Nagoya-shi, Japan

NHO Shikoku Cancer Center - Dept of Head and Neck Surgery

🇯🇵

Matsuyama-shi, Japan

Cancer Institute Hospital of JFCR - Dept of Medical Oncology

🇯🇵

Koto-ku, Japan

Aichi Cancer Center Hospital - Dept of Head and Neck Surgery

🇯🇵

Nagoya-shi, Japan

Okayama University Hospital - Dept of Otorhinolaryngology

🇯🇵

Okayama-shi, Japan

Osaka International Cancer Institute - Dept of Head and Neck Surgery

🇯🇵

Osaka-shi, Japan

Hokkaido University Hospital - Dept of Otorhinolaryngology

🇯🇵

Sapporo-shi, Japan

Kindai University Hospital - Dept of Oncology

🇯🇵

Osakasayama-shi, Japan

NHO Hokkaido Cancer Center - Dept of Oral Oncology Surgery

🇯🇵

Sapporo-shi, Japan

Tohoku University Hospital - Dept of Otorhinolaryngology/Head and Neck Surgery

🇯🇵

Sendai-shi, Japan

Yokohama City University Hospital - Dept of Otorhinolaryngology

🇯🇵

Yokohama-shi, Japan

Chonnam National University Hwasun Hospital

🇰🇷

Hwasun-gun, Korea, Republic of

Konkuk University Medical Center

🇰🇷

Seoul, Korea, Republic of

Seoul National University Bundang Hospital

🇰🇷

Seongnam, Korea, Republic of

Severance Hospital, Yonsei University Health System

🇰🇷

Seoul, Korea, Republic of

The Catholic University of Korea, St. Vincent's Hospital

🇰🇷

Suwon-si, Korea, Republic of

Pusan National University Yangsan Hospital

🇰🇷

Yangsan-si, Korea, Republic of

Hospital Civil Fray Antonio Alcalde - O.P.D. Hospital Civil de Guadalajara

🇲🇽

Guadalajara, Mexico

Centro de Atención e Investigación Clínica en Oncología

🇲🇽

Merida, Mexico

Amsterdam UMC, Locatie VUMC - Dept of Medical Oncology

🇳🇱

Amsterdam, Netherlands

Universitair Medisch Centrum Groningen - Cancer Center

🇳🇱

Groningen, Netherlands

UMC Utrecht - Dept Medical Oncology

🇳🇱

Utrecht, Netherlands

Instituto Português de Oncologia do Porto Francisco Gentil, EPE

🇵🇹

Porto, Portugal

S.C Medisprof S.R.L - parent

🇷🇴

Cluj-Napoca, Romania

S.C Centrul de Oncologie Sf. Nectarie S.R.L - parent

🇷🇴

Craiova, Romania

Complejo Hospitalario Universitario A Coruña - CHUAC-Hospital Teresa Herrera

🇪🇸

A Coruña, Spain

Complejo Hospitalario Universitario A Coruña - Servicio de Oncologia

🇪🇸

A Coruña, Spain

Hospital del Mar - Servicio de Oncologia

🇪🇸

Barcelona, Spain

Hospital Clinic de Barcelona - Medical Oncology

🇪🇸

Barcelona, Spain

Hospital Universitari Vall d'Hebron - Oncology Dept.

🇪🇸

Barcelona, Spain

ICO l'Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia

🇪🇸

Barcelona, Spain

ICO Badalona - Hospital Universitari Germans Trias i Pujol - Servicio de Oncologia Medica

🇪🇸

Barcelona, Spain

Hospital Universitario Lucus Augusti - Oncology

🇪🇸

Lugo, Spain

Clinica Universidad de Navarra (MAD) - Oncology Service

🇪🇸

Madrid, Spain

Hospital Universitario Fundacion Jimenez Diaz - Oncology

🇪🇸

Madrid, Spain

Hospital Universitario La Paz - Oncology Department

🇪🇸

Madrid, Spain

Hospital Universitario Virgen del Rocio - Oncology Service

🇪🇸

Sevilla, Spain

Istituto Oncologico della Svizzera Italiana (IOSI)- Ente Ospedaliero Cantonale (EOC) - Ospedale S.Giovanni

🇨🇭

Bellinzona, Switzerland

Hospital Regional Universitario de Malaga - Oncology Dept

🇪🇸

Málaga, Spain

CHUV, Lausanne University Hospital

🇨🇭

Lausanne, Switzerland

Chi Mei Hospital, Liouying

🇨🇳

Tainan, Taiwan

Changhua Christian Medical Foundation Changhua Christian Hospital

🇨🇳

ChangHua, Taiwan

Taipei Veterans General Hospital

🇨🇳

Taipei City, Taiwan

St James's University Hospital - Dept of Oncology

🇬🇧

Leeds, United Kingdom

Royal Marsden Hospital-London - Dept of Haematology/Oncology Research

🇬🇧

London, United Kingdom

Chaim Sheba Medical Center - pt

🇮🇱

Ramat Gan, Israel

© Copyright 2025. All Rights Reserved by MedPath